Both Eli Lilly and Novo Nordisk have invested in GLP-1 injectables manufacturing sites, with more capacity on the way. With a ribbon-cutting ceremony and tour on June 14, 2024, Lilly showed off its ...

Eli Lilly reported fourth-quarter revenue ... Among the company's efforts to expand production is a new manufacturing site in Concord, North Carolina. Ashkenazi said that the plant will initiate ...

This year's developments in the obesity market have really gone in Eli Lilly’s (NYSE:LLY) favor. Clinical trial results from competitors were largely underwhelming, including this week’s ...

ðÿ €üí—Õ×ï+{v7© ( dÓs]}Ý?)TLè¨0B ÓVþo­2îmŒÈ‹± úœÈûPõR==³p8{» HUõ«g{fú ñùÈ OàÈù vq 26.^f ª6[úÞfž B ÛM}ÿ!¤1‹ Ù ôêP>PuÁé)â&ø¿ÑÝ ¦[n ü¸Ø ...

Eli Lilly's obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after the drugs cost-effectiveness watchdog NICE on Monday gave its blessing.

Here’s a look at all your possible, practical options for internet service in Concord, North Carolina.

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. They're both leaders in the areas of insulin and broader diabetes drugs, where they've made significant breakthroughs ...

I n Southeastern Wisconsin, Eli Lilly and Company will invest $3 billion to expand a Kenosha County manufacturing facility it acquired from Nexus Pharmaceuticals Inc. earlier this year.

Eli Lilly and Novo Nordisk dominate the market for weight loss drugs, and demand for their products has surpassed supply in recent times. Lilly’s weight loss portfolio has already delivered ...

With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a welcome predicament: What to do with all that cash? One answer ...